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Hadron therapy was first proposed in 1946 and is by now widespread throughout the world, as witnessed
with the design and construction of the CNAO, HIT, PROSCAN and MedAustron treatment centres, among
others. The clinical interest in hadron therapy lies in the fact that it delivers precision treatment of
tumours, exploiting the characteristic shape (the Bragg peak) of the energy deposition in the tissues
for charged hadrons. In particular, carbon ion therapy is found to be biologically more effective, with
respect to protons, on certain types of tumours. Following an approach tested at NIRS in Japan [1], carbon
ion therapy treatments based on 12C could be combined or fully replaced with 11C PET radioactive ions
post-accelerated to the same energy. This approach allows providing a beam for treatment and, at the
same time, to collect information on the 3D distributions of the implanted ions by PET imaging. The pro-
duction of 11C ion beams can be performed using two methods. A first one is based on the production
using compact PET cyclotrons with 10–20 MeV protons via 14N(p,a)11C reactions following an approach
developed at the Lawrence Berkeley National Laboratory [2]. A second route exploits spallation reactions
19F(p,X)11C and 23Na(p,X)11C on a molten fluoride salt target using the ISOL (isotope separation on-line)
technique [3]. This approach can be seriously envisaged at CERN-ISOLDE following recent progresses
made on 11C+ production [4] and proven post-acceleration of pure 10C3/6+ beams in the REX-ISOLDE linac
[5]. Part of the required components is operational in radioactive ion beam facilities or commercial med-
ical PET cyclotrons. The driver could be a 70 MeV, 1.2 mA proton commercial cyclotron, which would lead
to 8.1  107 11C6+ per spill. This intensity is appropriate using 11C ions alone for both imaging and treat-
ment. Here we report on the ongoing feasibility studies of such approach, using the Monte Carlo particle
transport code FLUKA [6,7] to simulate pristine Bragg Peaks of 11C, in order to compare its performance
with 12C, in the context of hadron therapy.
 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In 2011, cancer accounted for about one quarter (26.3%) of the
total number of deaths in the European Union [8] and its treatment
still presents a challenge. Cancer therapy includes three major
types of treatment: surgery, chemotherapy/drugs and radiation
therapy, that are applied depending on the type of cancer, its loca-
tion and evolution. In particular, radiation plays an essential role in
cancer therapy and it is involved in 70% of the treatments [8]. Themain goal of radiation therapy is to deliver a maximally effective
dose of radiation to a tumour while sparing the surrounding
healthy tissue as much as possible.
Half of the patients treated with radiation are irradiated with
photons following the so-called conventional radiation therapy,
which also includes the use of electrons and of radioactive sources
in contact with the tumour (brachytherapy). The conventional
therapy with photons can be described by a decreasing exponential
absorption following a maximum as shown in Fig. 1. Following the
example depicted in Fig. 1, the maximum is observed at 2–3 cm
depth for beams with 8 MeV maximum energy [9], showing a poor
depth-dose dependence exhibited by photons. This feature is com-
pensated with the use of intensity modulated techniques (IMRT)
Fig. 1. Depth dependence of the deposited dose for different radiations [9].
Fig. 2. Set-up taking present devices, combining present accelerator components of
injection, at ISOLDE and MedAustron.
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methods are still not the most adequate for certain types of
tumours being the major problems associated with the volume of
healthy tissue exposed. Furthermore, for tumours near critical
organs this type of therapy is inappropriate.
The radiation therapy using fast hadrons (protons, neutrons and
ions) to treat tumours, so-called hadron therapy, presents several
advantages in particular in deep seated tumours or the ones near
critical organs. The concept dates back to 1946 when Robert Wil-
son has reported about the therapeutic interest of protons in can-
cer therapy [10]. The clinical advantage of hadron therapy is
related with the precise treatment of tumours making use of the
characteristic shape (the Bragg peak) of the energy deposition in
the tissues as shown in Fig. 1. Moreover, the Bragg peak allows
to target a well defined region at a precise depth in the body that
can be adjusted by tuning the energy of the incident beam, sparing
the surrounding healthy tissue.
Nowadays, protons are an important tool in clinical practice as
shown by the increasing number of hospital-based centres in oper-
ation and to the continuously increasing number of facilities pro-
posed worldwide [11]. On the other hand, very promising results
have been obtained with carbon ions, especially in the treatment
of specific radioresistant tumours types. In fact, carbon ions pre-
sent clear advantages such as higher biological effectiveness and
a better depth dose distribution due to a lower lateral diffusion
than protons. The first carbon therapy facilities in operation were
in Japan, Germany and Italy [1,12,13]. Data collected with carbon
ions in these facilities show promising effects on radio-resistant
tumours and lower post-treatment morbidity [14,15].
In addition to the mentioned advantages, the use of carbon per-
mits also the determination of the location where the dose is
deposited by means of on-line positron emission tomography
(PET) using 11C. This feature allows providing a beam for treatmentTable 1
Main parameters for 11C production.
Method Cyclotron Target Reaction In ta
prod
E [MeV] I[lA] [pps
PET production
(production batch)
22 150 N2
(61 atm)
14N(p,a)11C 3
REX-ISOLDE
(ISOL)
70 1200 NaF:LiF
eutectic
19F(p,2an)11C 4while collecting information on the 3D distributions of the
implanted ions by PET imaging. Therefore, carbon therapy treat-
ments based on 12C could be combined or fully replaced with 11C
radioactive ions post-accelerated at the same energy following an
approach tested in Japan [1]. In this paper we discuss the combina-
tion of stable ions used in hadron therapy with PET emitters of the
same chemical element following progresses made in the produc-
tion of 11CO+ beams [3] and in post-acceleration of pure 10C3/6+ [5].
Monte Carlo calculations using the FLUKA code have been per-
formed in order to assess the feasibility of such approach.2. 11C beam production
The production of 11C beams can be performed using the frag-
mentation method in which a high energy 12C beam, produced at
a synchrotron, irradiates a 7Be target. Other methods have been
developed and include the use of compact PET cyclotrons with
10–20 MeV protons where 30 GBq batches can be produced every
30 min exploiting 14N(p,a)11C reactions in high pressure N2 targets
[1,2]. One shall note that these targets cannot be directly con-
nected to typical ion sources for radioactive ion beam production
since the ion source operating pressure is several orders of magni-
tude lower than the required gas pressure. In PET-compound syn-
thesis modules, the N2 target bulk is released through a selective
trapping column which retains the produced 11CO2. This column
can be heated after to gradually release the 11CO2 for injection in
the ion source at relevant operating pressures allowing a continu-
ous 11CO2 delivery by using two extraction ports of a single cyclo-
tron and target modules in a sequential mode. As an illustrative
accelerator scheme, we adopt MedAustron’s machine parameters
[16,17]. This leads to an average injection rate of 3 1010 11CO2/s
in a electron cyclotron resonance (ECR) source used for 12C produc-
tion. Taking an average of 5% ionization efficiency using an ECR ion
source, 45% for transport and trapping efficiency, 30% for capture
and ionization in the charge breeder, an intensity of 1.5  108 11C
ions/spills can be delivered into a linac assuming a 10 ls pulse.
Assuming 90% for post-acceleration efficiency in the linac and an
overall 60% multi-turn injection and extraction efficiency in the
synchrotron, an intensity of 8.1  107 11C ions/spills is expected
from the synchrotron (Fig. 2).
An alternative route has recently been developed at CERN-
ISOLDE, exploiting the spallation reactions 19F(p,X)11C and 23Na
(p,X)11C on a molten fluoride target made of a NaF:LiF eutectic
and combined with a VADIS 1+ ion source [3]. The combination
of molten fluoride salt with the ISOL (isotope separation on-line)rget
uction
Trap charging
time
Injector Injector
repetition rate
Refs.
] (ms) [p/injection cycle] [Hz]
1010 741 1:5 108 1.3 [16,18]
1011 56 1:5 108 18 [4,5,16]
Fig. 3. FLUKA implementation of an heavy ion beam’s energy deposition as it
impinges in water.
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Fig. 4. Energy deposition (MeV/cm3/ppp) with 200 MeV/u heavy ion beam.
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of incoming proton beam. The pulsed 1.4 GeV Proton Synchrotron
Booster is not a particular suitable driver for 11C production. There-
fore, to reach more interesting in-target production yields, the
molten salt unit should be combined with a more appropriate pro-
ton driver such as the commercial cyclotrons delivering 70 MeV,
1.2 mA beam, which would lead to 8.1  107 11C6+/spills, assuming
5% ionization efficiency, 45% for transport and trapping, and 16.2%
for injection into the synchrotron. Although this intensity is still
lower than the nominal 4  108 ions/s requested in facilities like
MedAustron, it is appropriate to use 11C alone for both imaging
and treatment.
The layout of the low energy part of the accelerator chain before
injecting in the Linac will adopt a scheme similar to what has been
successfully operated in the existing ISOL facilities or used to inject
12C ions in hadron therapy facilities. The 1+? 6+ ion trapping,
charge breeding and beam injection will follow a similar scheme
to the one successfully demonstrated at REX-ISOLDE [5].
The feasibility studies including costs, efficiencies, maintenance
and operational requirements are ongoing. A summary of the main
parameters for 11C beam production is shown in Table 1. Finally,
one shall note that in the present proposal, the limitation comes
mostly from the trapping process. 1e-06
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Fig. 5. Fluence (ion/cm2) per primary (top) 11C and (Bottom) 12C, and the respective
secondary nuclei.3. Feasibility studies
The use of PET isotopes within hadron therapy protocols in
complete replacement of stable ions of the same element can be
performed if the radioactive counterpart can be produced in high
intensities. If the intensity is not high enough one can aim for a
combination with the stable ion beam. In the present study, one
is focused on the possibility of combining or fully replacing the
treatments with 12C by 11C ions treatment and dose mapping. To
plan a treatment for a patient with a certain tumour, it is required
to assess the quantity of the energy delivered and ensure it will
impact the right region. Monte Carlo simulations are, probably,
the only available tool that can describe accurately the dose deliv-
ery in a hadron therapy session in addition to accurate data on the
tumour shape and position inside the body as provided by CT/MRI
diagnostic devices. To simulate every session, the planning treat-
ments devised by oncologists rely in simple iterative algorithms
to calculate the dose, optimize the treatment efficiency, while mit-
igating costs and unnecessary exposure to radiation in conformity
with beam delivery accuracy. Nevertheless, their performance can
be improved to much higher levels once properly benchmarked.
To study the feasibility of the complete replacements of the
stable 12C by the PET 11C radioactive ion, the Monte Carlo code
FLUKA [6,7] has been used to calculate the energy deposition, the
production of secondary nuclei and secondary particles. As a firststep, tests have been performed by simulating the interaction of
heavy ions in water (Fig. 3) allowing to obtain the energy deposi-
tion and assess the impinging isotope range and the residuals pro-
duced throughout its path, plotted through FLUKA’s flair [19]
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Fig. 7. Fluence (particle/cm2) per primary for (top) 11C and (Bottom) 12C, and the
respective secondary particles.
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Fig. 6. Dose of different isotopes as percentage of primary for (top) 11C and
(bottom) 12C
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of 11C, 12C, 15O and 16O in water, as depicted in Fig. 3. Water was
preferred to any biological material at this stage as the objective
was to use the simplest parameters/geometry in order to easily
reproduce the Bragg peaks.
Fig. 4 illustrates the performance of some Heavy Ion beams,
with energy of 200 MeV/u, compared to 12C. Besides the energy
deposition profile and peak, it was necessary to further investigate
the fragmentation tail composition, as this tail is of foremost
importance in clinical context.
The second part of the present study was dedicated to the
assessment of the secondary nuclei and particles resulting from
the interaction of the primary particles in the beam path shown
in Figs. 5 and 7 for the nuclei and particles, respectively. Depending
on the type of ion used, the resulting secondary particles can have
their energies deposited locally (charged fragments) or farther
away (neutral fragments). The charged fragments will acquire
energies close to the projectile’s and, due to the A/Z2 Bragg peak
scaling for particles with equal velocity, they will deposit energy
beyond the Bragg Peak site if the charge of the fragment is smaller
than the primary one, leading to the additional out-of boundary
dose deposition seen as a fragmentation tail. As the primary ion
beam traverses water, it loses energy and different types of
ionising radiation are produced, particularly in the Bragg Peak
region. A portion of this radiation will consist of secondary nucleiproceeding from nuclear interactions as depicted in Fig. 5 including
isotopes which might themselves decay through the bþ emission,
emitting positrons and others that are transient states in the decay
chain.
The main differences observed in the produced secondary
nuclei are in the intensities of a-particles and Boron isotopes such
as 8B, 10B and 11B.
As for the dose contribution from these isotopes, it is evaluated
in Fig. 6, as percentage of total peak dose per primary particle.
Finally, regarding the production of other general secondary
radiation, it was obtained for 11C and 12C, with coinciding penetra-
tion depths (10 cm), using beams of 229.1 MeV/u and 217.7 MeV/u,
respectively. The value of beta and gamma (which can be used in
SPECT/CT) fluence in Fig. 7, particularly on the Bragg peak region
for 11C, is a powerful indicator of the imaging potential of these
ions for tridimensional mapping of the dose.
4. Summary
The first results of the feasibility studies of the combination of
full replacement of 12C by 11C do not present limitations due to
higher dose rates or energies showing that the replacement with
radioactive ion beam to be a possible alternative. The studies are
being extended to the investigation of the produced fragments as
well as to other possible PET emitters. The present studies and
future tests are envisaged within the forthcoming CERN-MEDICIS
378 R.S. Augusto et al. / Nuclear Instruments and Methods in Physics Research B 376 (2016) 374–378facility [20] and the MEDICIS-PROMED Horizon 2020 EU program
[21].
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